Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

PRICED: Novartis Capital Corp US$6bn 3s/5s/7s/10s/20s/30s 7-Pt

IGC European Market: Deal Flow - GeneralIGC US Market: Deal Flow - General

Novartis Capital Corp (NOVNVX) exp Aa3/AA- US$6bn SEC registered 7-part sr notes (3y FXD and/or FRN due 11/5/28, 5y FXD due 11/5/30, 7y FXD due 11/5/32, 10y FXD due 11/5/35, 20y FXD due 11/5/45 and 30y FXD due 11/5/55). MWC FXD tranches. 1mo par call on 3y FXD (10/5/28), 1mo on 5y (10/5/30), 2mos on 7y (9/5/32), 3mos on 10y (8/5/35), 6mos on 20y (5/5/45) and 6mos on 30y (5/5/55). Tax changes call on all tranches. Barc/BofA/HSBC/JPM (B&D) joint active books. Passive: BNP/DB/SG. Co-mgrs: Citi, Miz. Guarantor: Novartis AG. Denoms: 2,000 x 1,000. Sale into Canada: Yes - Exemption. UOP: general corporate purposes outside of Switzerland, including the refinancing of existing long- and short-term indebtedness. Pricing 11/3. Settle 11/5 (T+2). CUSIP: 3y FRN: 66989HBD9, 3y FXD: 6989HAX6, 5y: 66989HAY4, 7y: 66989HAZ1, 10y: 66989HBA5, 20y: 66989HBB3, 30y: 66989HBC1. ISIN: 3y FRN: US66989HBD98, 3y FXD: US66989HAX61, 5y: US66989HAY45, 7y: US66989HAZ10, 10y: US66989HBA59, 20y: US66989HBB33, 30y: US66989HBC16.

IPTs: 3y T+55 area and SOFR equiv, 5y T+70 area, 7y T+75 area, 10y T+80 area, 20y T+80 area, 30y T+90 area.
GUIDANCE: 3y FRN SOFR+52#, 3y FXD T+30#, 5y T+45#, 7y T+50#, 10y T+55#, 20y T+55#, 30y T+65#.
LAUNCHED: $800m 3y FRN at SOFR+52, $700m 3y FXD at T+30, $1.75bn 5y at T+45, $925m 7y at T+50, $925m 10y at T+55, $350m 20y at T+55, $550m 30y at T+65.

PRICED:
$800m 11/5/28 FRN at SOFR+52, at 100.
$700m 3.90% 11/5/28 99.978 3.908% T+30. MW+5.
$1.75bn 4.10% 11/5/30 99.700 4.167% T+45. MW+7.5.
$925m 4.30% 11/5/32 99.409 4.399% T+50. MW+7.5.
$925m 4.60% 11/5/35 99.564 4.655% T+55. MW+10.
$350m 5.20% 11/5/45 99.889 5.209% T+55. MW+10.
$550m 5.30% 11/5/55 99.464 5.336% T+65. MW+10.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.